Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$93.26
$0.37(1.44%)
At close: 4:00 PM EST
$93.26
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$17.88 - $98.70
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$4.93B
Enterprise Value$2.79B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue2.09K
Enterprise Value/Gross Profit2.22K
Enterprise Value/Ebitda-257.10
Forecast
1Y Price Target
$130.63Price Target Upside40.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.74
Revenue Forecast (FY)$1.18M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and rising equity/assets provide durable financial flexibility, allowing Dianthus to fund multi-year clinical programs without immediate refinancing. This reduces insolvency risk, supports R&D spending, and strengthens negotiating position for partnerships or acquisitions over the next several years.
Extended Cash Runway (~$1.2B)A roughly $1.2B cash position that management says can extend into 2030 materially de-risks near-term financing pressure, enabling completion of pivotal studies and multiple upcoming milestones. This runway gives time to achieve de-risking events before needing sizeable external capital, preserving strategic optionality.
Positive Phase 3 Interim Data & Pipeline BreadthA 75% responder rate in early Phase 3 materially improves the clinical probability of success for the lead program and supports an early-go decision, while DNTH212 expands autoimmune coverage. These durable clinical readouts and pipeline diversification increase the likelihood of eventual commercialization or partnerships.
Bears Say
Consistent Negative Cash FlowPersistent negative operating and free cash flow indicate ongoing cash burn driven by clinical development. Even with current runway, sustained negative cash generation means the company will likely rely on future financings or partnerships, creating dilution risk and constraining reinvestment if trials take longer or costs rise.
Widening Operating LossesMaterial and widening operating losses show that R&D and G&A scale currently overwhelm revenue, making near-term profitability unattainable. This structural loss profile persists until a product is commercialized or licensing revenues are secured, raising execution and return risks for long-term investors.
Volatile, Minimal Revenue BaseSmall, inconsistent revenue indicates the company remains pre-commercial and reliant on sporadic non-recurring sources or early collaborations. This revenue volatility increases dependence on successful trial outcomes to generate sustainable income and complicates multi-year planning and resource allocation.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $17.88 and its highest was $98.70 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $4.93B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.072 by $0.222.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 54,666,233 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.072. Following the earnings report the stock price went up 0.199%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.63 (40.07% Upside)
$130.63 (40.07% Upside)
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-1.78%
Trailing 12-Months
Asset Growth
257.70%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$130.63
▲(40.07% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.13% Insiders
26.12% Mutual Funds
55.84% Other Institutional Investors
5.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---